ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.896,50
-0,14%
S&P 500
5.041,40
0,46%
Dow Jones
38.084,02
0,48%
Euro vs US Dollar
1,07041
-0,13%
Bitcoin
59.127,79
1,53%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) News

LXRX Lexicon Pharmaceuticals Inc

1,715
0,065 (3,94%)
Zuletzt aktualisiert: 17:49:13
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Lexicon Pharmaceuticals Inc LXRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,065 3,94% 1,715 17:49:13
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,73 1,65 1,75 1,65
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
29.4.202415:00GLOBELonnel Coats Retires as Chief Executive Officer and Board..
29.4.202413:00GLOBELexicon Pharmaceuticals to Host First Quarter 2024 Financial..
18.4.202414:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03.4.202414:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
25.3.202414:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12.3.202413:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
11.3.202421:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11.3.202412:26EDGAR2Form 8-K - Current report
11.3.202412:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11.3.202412:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11.3.202412:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
29.2.202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202413:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
29.12.202323:29EDGAR2Form 8-K - Current report
29.12.202323:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.12.202322:04EDGAR2Form 8-K - Current report
21.12.202322:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30.11.202313:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22.11.202313:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
17.11.202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.11.202323:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.11.202320:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
10.11.202322:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
08.11.202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202313:22EDGAR2Form 8-K - Current report
08.11.202313:00GLOBELexicon Pharmaceuticals Reports Third Quarter 2023 Financial..
03.11.202314:00GLOBELexicon Pharmaceuticals to Host Third Quarter 2023 Financial..
02.11.202314:00GLOBEData on Early Clinical Benefit for INPEFA® (Sotagliflozin)..
01.11.202314:00GLOBEINPEFA® (Sotagliflozin) Receives Coverage From Express..
31.10.202321:01GLOBELexicon Strengthens Management Team With Two New Executives
30.10.202321:01GLOBENew Data Relating to Sotagliflozin to be Presented at the..
17.10.202322:01GLOBEData From Two Studies Demonstrating Positive Financial..
11.10.202322:06EDGAR2Form 8-K - Current report
11.10.202322:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.10.202322:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
11.10.202315:00GLOBEData Demonstrating Financial Impact of INPEFA®..
09.10.202322:01GLOBEINPEFA® (Sotagliflozin) Receives Preferred Formulary Status..
09.10.202314:00GLOBETom Garner Joins Lexicon as Senior Vice President and Chief..
28.9.202315:00GLOBELexicon to Present Post Hoc Analysis of Scored Clinical..
26.9.202315:00GLOBELexicon to Present Study Results Relating to Sotagliflozin..

Kürzlich von Ihnen besucht

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten